An Open-label Eslicarbazepine Acetate Long-term Safety and Tolerability Study in Children and Adolescents (4 - 17 Years)
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2017
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions
- Sponsors Sunovion Pharmaceuticals
- 16 Nov 2017 Status changed from active, no longer recruiting to discontinued.
- 21 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.